Effects of Acetylsalicylic Acid on Inhibition of Ex Vivo Platelet Aggregation and Secretion by SKF 107260, a Novel GPIIb/IIIa Receptor Antagonist

Summary

SKF 107260 is a potent pentapeptide antagonist of the platelet membrane glycoprotein receptor GP IIb/IIIa. The in vitro platelet inhibitory effects of SKF 107260, acetylsalicylic acid (ASA), and their combination, on collagen-induced platelet aggregation and secretion (ATP release) were assessed in human whole blood. Additionally, the con-centration-response relationships for these inhibitors were compared for males and females in order to explore gender differences in platelet responsiveness. SKF 107260 caused a concentration-dependent inhibition of platelet aggregation which was significant at concentrations ≥30 nM. ASA also caused a concentration-dependent inhibition of platelet aggregation which was significant at concentrations ≥ 1 mg/dl. The addition of ASA 1 mg/dl to increasing concentrations of SKF 107260 resulted in a more pronounced inhibition of platelet aggregation than when either agent was used alone. These data suggest a pharmacologic interaction, especially at SKF 107260 concentrations ≤30 nM. Since ATP release was significantly inhibited at concentrations ≥ 1 nM, platelet secretion appears to be more sensitive than aggregation to inhibition by SKF 107260. These data suggest that platelet secretion in response to collagen is dependent on the aggregation response mediated by GP IIb/IIIa. In conclusion, SKF 107260 is a potent inhibitor of both whole blood platelet aggregation and secretion and these anti-aggregatory effects may be augmented by concomitant ASA administration.

• References

• 1 Kieffer N, Phillips DR. Platelet membrane glycoproteins: functions in cellular interactions. Annu Rev Cell Biol 1990; 6: 329-357
• 2 Ruoslahti E, Pierschbacher MD. New perspectives in cell adhesion: RGD and integrins. Science 1987; 238: 491-497
• 3 Coller BS, Folts JD, Scudder LE, Smith SR. Antithrombotic effect of a monoclonal antibody to the platelet glycoprotein IIb/IIIa receptor in an experimental model. Blood 1986; 68: 783-786
• 4 Shebuski RJ, Berry DE, Bennett DB, Romoff T, Storer BL, Ali F, Samanen J. Demonstration of Ac-Arg-Gly-Asp-Ser-NH₂ as an antiaggregatory agent in the dog by intracoronary administration. Thromb Haemost 1989; 61: 183-188
• 5 Nichols AJ, Ruffolo Jr RR, Huffman WF, Poste G, Samanen J. Development of GPIIb/IIIa antagonists as antithrombotic drugs. Trends Pharmacol Sci 1992; 13: 413-417
• 6 Nichols AJ, Vasko J, Koster P, Smith J, Barone F, Nelson A, Stadel J, Powers D, Rhodes G, Miller-Stein C, Boppana V, Bennet D, Berry D, Romaff T, Calvo R, Ali F, Sorenson E, Samanen J. SKF 106760, a novel GP IIb/IIIa antagonist: antithrombotic activity and potentiation of streptokinase-mediated thrombolysis. Eur J Pharmacol 1990; 183: 2019
• 7 Willette RN, Sauermelch CF, Rycyna R, Sarkar S, Feuerstein GZ, Nichols AJ, Ohlstein EH. Antithrombotic effects of a platelet fibrinogen receptor antagonist in a canine model of carotid artery thrombosis. Stroke 1992; 23: 703-711
• 8 Davison C. Salicylate metabolism in man. Ann NY Acad Sci 1971; 179: 249-268
• 9 Dunnett CW. A multiple comparisons procedure for comparing several treatments with a control. JASA 1955; 50: 1096-121
• 10 Tukey JW. The problem of multiple comparisons. Princeton University, Princeton, N J 1953 (Photocopy of transcript)
• 11 Kelton JG, Powers P, Julian J, Boland V, Carter CJ, Gent M, Hirsh J. Sex-related differences in platelet aggregation: influence of the hematocrit. Blood 1980; 56: 38-41
• 12 Perutelli P, Mori PG. The human platelet membrane glycoprotein IIb/IIIa complex: a multifunctional adhesion receptor. Haematologica 1992; 77: 162-168
• 13 Samanen J, Ali F, Romoff T, Calvo R, Sorenson E, Vasko J, Storer B, Berry D, Bennett D, Strohsacker M, Powers D, Stadel J, Nichols A. Development of a small RGD peptide fibrinogen receptor antagonist with potent antiaggregatory activity in vitro. J Med Chem 1991; 34: 3114-3125
• 14 Tallarida RJ, Porreca F, Cowan A. Statistical analysis of drug-drug and site-site interactions with isobolograms. Life Sci 1989; 45: 947-961
• 15 Tallarida RJ. Statistical analysis of drug combinations for synergism. Pain 1992; 49: 93-97
• 16 Roper P, Drewinko B, Hasler D, Johnston D, Hester J, Freireich EJ. Effects of time, platelet concentration, and sex on the human platelet aggregation response. Am J Clin Pathol 1979; 71: 263-268
• 17 Johnson M, Ramey E, Ramwell PW. Sex and age differences in human platelet aggregation. Nature 1975; 253: 355-357
• 18 De la Cruz JP, Bellido I, Camara S, Sanchez de la Cuesta F. Aspirin sex difference on platelet aggregation in human whole blood: influence of estradiol and thromboxane levels. Rev Farmacol Clin Exp 1987; 4: 109-113
• 19 Hardisty RM, Hutton RA, Montgomery D, Rickard S, Trebilcock H. Secondary platelet aggregation: a quantitation study. Br J Haematol 1970; 19: 307-319
• 20 Aguilar Munoz A, De la Cruz Cortes JP, Martos Crespo F, De Pablo Molina JP, Sanchez de la Cuesta F. Efecto sobre algunos pardmetros pla-quetarios de dipiridamol (225 mg/dia), acido acetilsalicilico (150mg/dia) y su asociacion en voluntarios sanos. Med Clin 1985; 85: 743-745
• 21 De la Cruz Cortes JP, Martos Crespo F, Bellido I, Sanchez de la Cuesta F. Inhibicion “in vitro” con dipiridamol de la agregacion plaquetaria inducida por ADP en sangre total y plasma. Rev Farmacol Clin Exp 1985; 2: 51-53